External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

Jiangsu Recbio Technology / Equity Bottom-Up

<ul><li>9-Valent HPV Vaccine, REC603: The Ph III trial of REC603 in females aged 9-45, which recruited a total of 16,050 subjects, is in process.</li><li>Recbio has completed three doses vaccination of immune-bridging trial in younger age groups and the immunogenicity comparative trial with Gardasil®9.</li><li>The Company now follows up on the subjects of primary efficacy trial. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

9-Valent HPV Vaccine, REC603: The Ph III trial of REC603 in females aged 9-45, which recruited a total of 16,050 subjects, is in process.Recbio has completed three doses vaccination of immune-bridging trial in younger age groups and the immunogenicity comparative trial with Gardasil®9.The Company now follows up on the subjects of primary efficacy trial. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Recbio (2179 HK) – Clinical Development of Core Pipeline Products Continues

<ul><li>Recbio announced positive results in the Phase II study of its COVID vaccine ReCOV which compared the immunogenicity and safety to Pfizer’s mRNA vaccine, COMIRNATY®, as a booster vaccination.</li><li>The head-to-head trial enrolled 600 subjects with basic immunization of two doses of inactive vaccines in the Philippines and the results were upon 14 days post-booster.</li><li>Statistical superiority in immunogenicity vs. COMIRNATY® against both prototype strains and Omicron strains.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Recbio announced positive results in the Phase II study of its COVID vaccine ReCOV which compared the immunogenicity and safety to Pfizer’s mRNA vaccine, COMIRNATY®, as a booster vaccination.The head-to-head trial enrolled 600 subjects with basic immunization of two doses of inactive vaccines in the Philippines and the results were upon 14 days post-booster.Statistical superiority in immunogenicity vs. COMIRNATY® against both prototype strains and Omicron strains.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Recbio (2179 HK) – Superior immunogenicity on ReCOV vs. Pfizer’s mRNA vaccine

<div><div><div><ul><li>Recbio reported RMB350mn net loss for 1H22, vs RMB330mn net loss in 1H21.</li><li>R&amp;D expense increased by 73% YoY to RMB354mn in 1H22, mainly due to clinical trial expenses related to the Ph III trial of REC603 and PhII/III trials of ReCOV.</li><li>On 25 Aug, Recbio received a formal acceptance letter from China Securities Regulatory Commission, for the implementation of its H Share full circulation plan to convert 222.5mn Domestic Shares into H Shares.</li></ul></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Recbio reported RMB350mn net loss for 1H22, vs RMB330mn net loss in 1H21.R&amp;D expense increased by 73% YoY to RMB354mn in 1H22, mainly due to clinical trial expenses related to the Ph III trial of REC603 and PhII/III trials of ReCOV.On 25 Aug, Recbio received a formal acceptance letter from China Securities Regulatory Commission, for the implementation of its H Share full circulation plan to convert 222.5mn Domestic Shares into H Shares.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Recbio Technology (2179 HK) – Smooth progress of core pipeline products

China

Jiangsu Recbio Technology is an innovative vaccine company dedicated to the research, development, production, and commercialization of recombinant protein vaccines and related adjuvant technologies. Its pipeline includes vaccines for cervical cancer, shingles, COVID-19, influenza, and tuberculosis. The company was founded in 2012 and is headquartered in Taizhou, Jiangsu, PRC.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jiangsu Recbio Technology (2179 HK)

Recbio (2179 HK) – Clinical Development of Core Pipeline Products Continues

9-Valent HPV Vaccine, REC603: The Ph III trial of REC603 in females aged 9-45, which recruited a total of 16,050 subjects, is in process.

CMB International

Recbio (2179 HK) – Superior immunogenicity on ReCOV vs. Pfizer’s mRNA vaccine

Recbio announced positive results in the Phase II study of its COVID vaccine ReCOV which compared the immunogenicity and safety to Pfizer’s mRNA...

CMB International

Recbio Technology (2179 HK) – Smooth progress of core pipeline products

R&D expense increased by 73% YoY to RMB354mn in 1H22, mainly due to clinical trial expenses related to the Ph III trial of REC603 and PhII/III...

CMB International

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)